NASDAQ$ATYR
aTyr Pharma Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close
Briefing
ATYR reported Q4 2025, net loss of $40M.
For Q4 2025, ATYR reported a net loss of $40M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Net loss $40M.
- ATYR MD&A covers liquidity, credit, and operating priorities.
- ATYR MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
aTyr Pharma Inc · Revenue · Quarterly
$0
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks; numeric multi-quarter bridges vary by issuer.
Tailwinds
- MD&A highlights liquidity, capital, and core business trends.
- Segment or product commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure near-term margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2025
-2.0%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+10.0%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+7.4%
Q2 2020
Best reaction
-8.6%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -8.6% | +2.2% | -6.1% | |
| Q3 2025 | -5.4% | -3.3% | +1.2% | |
| Q1 2025 | -2.2% | +0.3% | +66.6% | |
| Q3 2024 | -4.6% | +7.4% | +3.4% | |
| Q2 2024 | -3.9% | +5.5% | +3.3% | |
| Q1 2024 | +0.6% | +6.9% | +8.8% | |
| Q3 2023 | -5.7% | -9.0% | -1.6% | |
| Q4 2022 | +1.0% | -3.6% | -1.0% | |
| Q4 2021 | +0.0% | +6.5% | +4.2% | |
| Q3 2021 | +1.2% | -1.7% | -7.0% | |
| Q2 2021 | +0.8% | -2.3% | +14.2% | |
| Q1 2021 | +1.7% | +11.6% | +31.2% | |
| Q3 2020 | +0.6% | -1.8% | +38.1% | |
| Q2 2020 | +7.4% | +20.6% | -1.4% | |
| Q1 2020 | -5.4% | -6.1% | -15.9% | |
| Q3 2019 | -6.2% | -3.9% | +7.2% | |
| Q2 2019 | -5.7% | +4.7% | +24.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro